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Supplementary Material for Lewis et al 2017 
 
Supplementary Methods 
Protein array analysis 
The Discovery Array version 3.0 protein microarray employed in this study has been developed to 
display native, discontinuous epitopes using previously described technology [1, 2]. Full-length 
human proteins were expressed with a biotin carboxyl carrier protein (BCCP)-myc folding tag via 
baculovirus vector in Sf9 insect cells. Each cell line was Sanger sequenced to ensure correct 
subcloning. Biotinylation of the BCCP tag, which requires correct folding of the BCCP sequence, 
was used to screen for correct protein folding. All cell lines were subject to rigorous quality control 
measures including being tested by Western blot to confirm synthesis of a single biotinylated 
protein product of correct molecular weight, reliable and consistent protein expression over time 
and consistent plating density across arrays. Proteins were arrayed on streptavidin-coated, 
HydroGel-derivatized Schott Nexterion glass slides (Schott, Jena, Germany) in a specific, oriented 
manner designed to conserve native epitopes. Each microarray contained human proteins 
representing 1543 distinct genes chosen from multiple functional and disease pathways printed in 
quadruplicate together with control proteins: four control proteins for the BCCP-myc tag (BCCP, 
BCCP-myc, β-galactosidase-BCCP-myc and β-galactosidase-BCCP) and additional controls 
including Cy3-labeled biotin-BSA, dilution series of biotinylated-IgG and biotinylated IgM and 
buffer-only spots. 
 Microarrays were incubated with serum samples to allow detection of binding of serum 
immunoglobulins to specific proteins on the arrays, enabling the identification of both auto-
antibodies and their cognate antigens, as previously described [3]. In brief, following clarification 
by centrifugation, samples were diluted 200-fold in 0.1% v/v Triton/0.1% v/v BSA in 1x PBS 
(Triton-BSA buffer) and then applied to the arrays. Following incubation for 2 hours at 20°C with 
gentle shaking (50 rpm), arrays were washed three times in fresh Triton-BSA buffer at 20°C for 20 
minutes with gentle shaking. The washed arrays were then incubated with labelled anti-human IgG 
antibody) at 20°C for 2 hours. Arrays were washed three times in Triton-BSA buffer for 5 minutes 
at 20°C, rinsed briefly (5-10 seconds) in distilled water, and centrifuged for 2 minutes at 240g. 
Each batch of microarrays was also tested with a pooled normal human sera control as an internal 
check of background reproducibility across different experiments over time. 
 The probed and dried arrays were scanned using a High-Resolution microarray scanner 
(Agilent Technologies, Santa Clara, CA, USA) at 10µm resolution. The resulting 20-bit TIFF 
images were feature extracted using Feature Extraction software version 10.5 or 10.7.3.1 (Agilent 




Raw median signal intensity of each protein feature on the array was subtracted from the local 
median background intensity and fluorescence intensity for each autoantigen normalised by 
consolidating the replicates (median consolidation), followed by normal transformation and then 
global median normalisation. Outliers were identified and removed. Statistical analysis was 
performed using R statistics version 3.3.2 (R Foundation for Statistical Computing, Vienna, 
Austria) and Prism (GraphPad Software, La Jolla, CA, USA). No significant underlying structure 
between discovery and validation datasets was observed using principal component (Figure S2). 
Autoantibodies were tested in the discovery dataset by comparing SLE patients and controls using a 
linear regression model adjusting for age, sex, ancestry/ethnicity and country (UK/US), with P 
values corrected for false discovery rate (FDR) using Storey’s Q value. Significantly increased 
autoantibodies (n=226) were tested in the validation dataset using the same regression model. A 
post-validation meta-analysis was performed using a linear regression model adjusting for age, sex, 
ancestry/ ethnicity and cohort. Autoantibody positivity was defined as autoantibody levels >2 SD of 
the control population, tested for statistical significance using Fisher’s exact test, corrected using 
FDR. Autoantibodies were checked for non-significant levels of positivity in the confounding 
group. 
 Unsupervised hierarchical clustering of autoantibody levels was performed separately in the 
discovery and validation datasets SLE patients using correlation as distance metric with Ward’s 
method for clustering and plotted as heatmaps for each dataset in R. Supervised principal 
component analysis was performed with 79 autoantibodies validated in both datasets using SLE 
individuals and controls. Correlation between antibody clusters was confirmed using corrplot 
function. For linear discriminant analysis (LDA), correlated autoantibody groupings with Pearson 
r>0.8 were rationalised to a single autoantibody to prevent multi-collinearity. LDA was performed 
on SLE patients (n=277) and controls (n=280) using R package MASS and 3D plots visualised 
using R packages plot3d and rgl. 
 
Machine learning and predictive models 
Multiple machine learning methods were applied to the data, using the discovery cohort as the 
training dataset and tested in the validation dataset. Elastic net regularised binomial logistic 
regression was performed using R package glmnet with L1-L2 tuning parameter α and shrinkage 
parameter λ selected by 10-fold cross-validation on the discovery dataset. This identified a 17-
autoantibody model. Predictive models were tested on the validation dataset by Receiver operating 
characteristic (ROC) curve analysis using R package pROC. Multinomial elastic net logistic 
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regression was used for variable selection for discrimination of control group and 4 SLE patient 
clusters in the validation dataset. Tuning of α and λ regularisation parameters by 10-fold cross-
validation identified an optimal set of 26 autoantibodies for control group and 4 SLE patient 
clusters separation. The 26-autoantibody panel was fitted to a ridge regression penalised mixture 
discriminant analysis (MDA) model using R package mda, specifying 1 control cluster and 4 SLE 
clusters. 97.9% of between-group variance could be explained by 3 canonical variates, so the MDA 
model was simplified to 3 canonical variate dimensions. The MDA model was tested in the 
validation dataset by ROC curve analysis. All model formulae are documented in Table S4 (below). 
Decision boundaries in the canonical variate subspace were calculated in R using the predict.mda 
function. 
 
Protein-protein interaction analysis 
Autoantigens identified by the array were imported into STRING database version 10 (Search Tool 
for the Retrieval of Interacting Genes/Proteins) and human protein-protein interactions retrieved 
with predicted nodes identified by STRING. Data was exported and protein-protein interaction 
networks were visualised in Cytoscape version 3.2.1. 
 
Genotyping and HLA imputation 
SNP genotype data using the Illumina Human Omni1-Quad BeadChip platform was available on a 
subset of UK SLE individuals (n=44), who were also part of a genome-wide association study in 
European SLE individuals [4]. HLA alleles were imputed as previously described and alleles with 
minor allele frequency <5% were excluded. Statistical analysis was performed using linear 




Table S1. Characteristics of Discovery and Validation datasets 
 
  
Discovery dataset Validation dataset
Control SLE P value Control SLE Confounding P value*
n 188 186 92 91 92
Age (y) 38.8 ± 9.5 39.4 ± 12.7 0.61 38.8 ± 10.5 40.3 ± 12.5 46.5 ± 12.0 0.39
Sex female/male (%) 188/0 (100/0) 177/9 (95/5) 0.002 92/0 (100/0) 89/2 (98/2) 82/10 (89/11) 0.25
Ancestry/ethnicity
   African 76 (40%) 79 (42%) 0.87 35 (38%) 38 (42%) 34 (37%) 0.86
   European 91 (48%) 89 (48%) 42 (46%) 41 (45%) 58 (63%)
   Hispanic 21 (11%) 18 (10%) 12 (13%) 12 (13%) 0 (0%)
Country
   USA 60 (32%) 56 (30%) 0.74 30 (33%) 29 (32%) 0 (0%) 1.00
   UK 128 (68%) 130 (70%) 62 (67%) 62 (68%) 92 (100%)
*P value for Control vs SLE
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location P FDR P FDR P FDR Novel Ref
TROVE2 Ro60, SSA2 6738 1q31 1.84E-16 1.14E-13 6.56E-11 3.99E-09 1.21E-25 1.86E-22 no
SSB/La 6741 2q31.1 5.62E-15 1.74E-12 4.94E-11 3.99E-09 2.37E-24 1.82E-21 no
PABPC1 26986 8q22.2-q23 1.06E-13 2.18E-11 4.90E-05 7.45E-04 2.18E-17 1.11E-14 no [5]
HMGB2 HMG2 3148 4q31 1.68E-12 2.59E-10 1.06E-03 4.85E-03 1.28E-14 3.59E-12 no [6]
HNRNPA2B1 SNRPB1 3181 7p15 9.57E-12 9.85E-10 2.56E-04 1.73E-03 1.26E-14 3.59E-12 no [7, 8]
HNRNPUL1 E1B-AP5 11100 19q13.2 4.76E-11 4.20E-09 7.90E-05 8.78E-04 1.40E-14 3.59E-12 yes
ANXA1 LPC1 301 9q21.13 2.53E-10 1.74E-08 2.40E-05 4.17E-04 3.11E-14 6.33E-12 no [9]
LIN28A 79727 1p36.11 5.36E-12 6.63E-10 1.46E-03 5.95E-03 3.30E-14 6.33E-12 yes
IGF2BP3 10643 7p11 1.32E-10 1.02E-08 8.84E-05 8.78E-04 5.96E-14 1.02E-11 yes
DLX4 1748 17q21.33 2.53E-09 1.56E-07 1.56E-05 4.17E-04 1.54E-13 2.37E-11 yes
APOBEC3G ARP-9 60489 22q13.1 9.19E-08 3.55E-06 2.18E-05 4.17E-04 1.15E-11 1.61E-09 yes
PSME3 Ki, PA28-gamma 10197 17q21 3.50E-07 1.27E-05 1.08E-05 4.17E-04 1.64E-11 2.10E-09 no [10]
HMG20B 10362 19p13.3 4.33E-09 2.43E-07 1.18E-03 5.13E-03 5.59E-11 6.60E-09 yes
CDC25B 994 20p13 1.44E-06 4.25E-05 9.38E-05 8.78E-04 5.19E-10 5.69E-08 yes
RRAS 6237 19q13.33 1.23E-06 3.80E-05 1.31E-04 1.06E-03 6.33E-10 6.48E-08 yes
NFIL3 E4BP4, IL3BP1 4783 9q22 5.02E-07 1.71E-05 3.46E-04 2.21E-03 7.10E-10 6.81E-08 yes
FUS HNRNPP2 2521 16p11.2 6.70E-08 2.96E-06 5.91E-03 1.56E-02 1.53E-09 1.30E-07 yes
PRM1 5619 16p13.2 4.67E-06 1.15E-04 8.40E-05 8.78E-04 2.30E-09 1.86E-07 yes
HOXB6 3216 17q21.3 5.85E-09 3.01E-07 1.13E-02 2.31E-02 6.03E-09 4.63E-07 yes
SMAD5 4090 5q31 1.05E-04 8.20E-04 2.11E-05 4.17E-04 5.25E-08 3.42E-06 yes
ATF4 CREB-2 468 22q13.1 2.36E-05 3.10E-04 4.30E-03 1.28E-02 3.74E-07 1.85E-05 yes
ARAF 369 Xp11.4 2.00E-04 1.29E-03 2.45E-04 1.73E-03 4.47E-07 2.08E-05 no [11]
IRF5 3663 7q32 5.04E-05 5.19E-04 2.29E-03 8.98E-03 4.44E-07 2.08E-05 yes
NEUROD4 58158 12q13.2 2.19E-04 1.33E-03 4.66E-04 2.58E-03 6.77E-07 2.81E-05 yes
SMAD2 4087 18q21.1 9.24E-04 3.36E-03 1.78E-04 1.35E-03 6.45E-07 2.81E-05 yes
CARHSP1 23589 16p13.2 7.77E-06 1.51E-04 2.63E-02 4.10E-02 9.19E-07 3.55E-05 yes
BIRC3 c-IAP2 330 11q22 2.24E-05 3.01E-04 1.52E-02 2.89E-02 1.03E-06 3.85E-05 yes
VAV1 VAV 7409 19p13.2 2.40E-04 1.40E-03 1.47E-03 5.95E-03 1.49E-06 5.07E-05 yes
PLD2 5338 17p13.1 1.11E-04 8.41E-04 3.82E-03 1.28E-02 1.67E-06 5.46E-05 yes
PATZ1 ZNF278 23598 22q12.2 3.32E-04 1.78E-03 8.26E-04 4.19E-03 1.72E-06 5.50E-05 yes
PRM2 5620 16p13.2 6.67E-04 2.73E-03 1.05E-04 9.15E-04 1.91E-06 5.87E-05 yes
TGIF1 7050 18p11.3 3.64E-05 4.24E-04 2.01E-02 3.48E-02 1.90E-06 5.87E-05 yes
ZAP70 7535 2q12 2.68E-05 3.30E-04 2.59E-02 4.09E-02 2.19E-06 6.58E-05 yes
LYN 4067 8q13 9.86E-05 7.81E-04 8.49E-03 2.05E-02 2.36E-06 6.96E-05 yes
EZH2 2146 7q35-q36 4.05E-04 2.00E-03 1.08E-03 4.85E-03 2.48E-06 7.17E-05 yes
MLF1 4291 3q25.1 2.23E-04 1.34E-03 4.62E-03 1.34E-02 3.81E-06 1.06E-04 yes
SSX4 6759 Xp11.23 2.03E-05 2.79E-04 9.37E-03 2.05E-02 4.16E-06 1.10E-04 yes
GNG4 2786 1q42.3 1.89E-03 5.42E-03 3.63E-04 2.21E-03 4.52E-06 1.15E-04 yes
CREB1 CREB 1385 2q34 7.43E-05 6.75E-04 2.13E-02 3.51E-02 4.84E-06 1.22E-04 yes
PPP2R5A 5525 1q32.2 5.54E-04 2.36E-03 3.62E-03 1.26E-02 5.94E-06 1.42E-04 yes
PPP2CB 5516 8p12 2.33E-03 6.09E-03 3.92E-04 2.27E-03 6.78E-06 1.58E-04 yes
IRF4 3662 6p25-p23 1.32E-04 9.59E-04 1.85E-02 3.35E-02 7.80E-06 1.73E-04 yes
MLLT3 4300 9p22 1.49E-04 1.06E-03 1.76E-02 3.30E-02 8.01E-06 1.76E-04 yes
RPL10 6134 Xq28 3.02E-04 1.64E-03 1.01E-02 2.11E-02 8.49E-06 1.79E-04 no [12]
CRX 1406 19q13.3 5.74E-04 2.41E-03 4.10E-03 1.28E-02 8.93E-06 1.85E-04 yes
HIST1H4I 8294 6p21.33 4.39E-04 2.07E-03 9.12E-03 2.05E-02 1.26E-05 2.51E-04 yes
RPL18A 6142 19p13 5.11E-04 2.31E-03 1.14E-02 2.31E-02 1.62E-05 3.00E-04 yes
SMN1 6606 5q13.2 3.83E-03 8.66E-03 9.65E-04 4.70E-03 1.79E-05 3.22E-04 yes
WT1 7490 11p13 8.32E-04 3.13E-03 5.55E-03 1.50E-02 1.84E-05 3.22E-04 yes
APEX1 328 14q11.2 5.61E-03 1.13E-02 7.75E-04 4.10E-03 2.08E-05 3.44E-04 no [13]
MAP3K7 MEKK7, TAK1 6885 6q15 1.13E-03 3.90E-03 9.43E-03 2.05E-02 3.44E-05 5.20E-04 yes
BCL2A1 597 15q24.3 1.73E-02 2.54E-02 7.01E-05 8.78E-04 3.93E-05 5.74E-04 yes
EGR2 KROX2 1959 10q21.1 5.25E-04 2.33E-03 3.18E-02 4.78E-02 4.66E-05 6.49E-04 yes
MYD88 4615 3p22 1.93E-03 5.48E-03 8.46E-03 2.05E-02 6.12E-05 8.16E-04 yes
MAP3K14 NIK 9020 17q21 4.23E-03 9.19E-03 3.13E-03 1.12E-02 7.75E-05 9.82E-04 no [14]
EFS 10278 14q11.2 3.38E-03 7.81E-03 9.38E-03 2.05E-02 1.06E-04 1.23E-03 yes
SUB1 p14 10923 5p13.3 5.24E-03 1.08E-02 4.91E-03 1.39E-02 1.17E-04 1.33E-03 yes
TWIST2 117581 2q37.3 2.83E-03 7.12E-03 1.82E-02 3.35E-02 1.37E-04 1.52E-03 yes
MYOZ2 51778 4q26-q27 6.83E-03 1.29E-02 7.88E-03 2.04E-02 1.80E-04 1.85E-03 yes
DSTYK RIPK5 25778 1q32.1 1.08E-02 1.83E-02 4.20E-03 1.28E-02 1.86E-04 1.89E-03 yes
MYF6 4618 12q21 1.29E-02 2.09E-02 2.94E-03 1.08E-02 1.99E-04 2.00E-03 yes
ME2 4200 18q21 4.53E-03 9.64E-03 1.92E-02 3.44E-02 2.37E-04 2.30E-03 yes
PRKRA 8575 2q31.2 8.01E-03 1.45E-02 8.34E-03 2.05E-02 2.43E-04 2.31E-03 yes
TGIF2 60436 20q11.23 1.16E-02 1.90E-02 9.72E-03 2.07E-02 3.04E-04 2.65E-03 yes
RPS7 6201 2p25 1.87E-02 2.69E-02 4.26E-03 1.28E-02 3.51E-04 2.98E-03 yes
FOXM1 2305 12p13 6.64E-03 1.27E-02 2.35E-02 3.82E-02 3.90E-04 3.23E-03 yes
RAPGEF4 11069 2q31-q32 2.19E-02 3.00E-02 2.58E-03 9.79E-03 4.44E-04 3.55E-03 yes
RPS2 6187 16p13.3 1.73E-02 2.54E-02 5.22E-03 1.44E-02 4.86E-04 3.80E-03 yes
FOSL1 8061 11q13 8.46E-03 1.53E-02 2.88E-02 4.44E-02 5.98E-04 4.57E-03 yes
HOXB7 3217 17q21.3 1.72E-02 2.54E-02 1.45E-02 2.79E-02 7.37E-04 5.28E-03 yes
MMP2 4313 16q12.2 2.05E-02 2.87E-02 9.23E-03 2.05E-02 8.80E-04 6.14E-03 yes
RQCD1 CNOT9 9125 2q35 2.47E-02 3.23E-02 8.96E-03 2.05E-02 8.84E-04 6.14E-03 yes
EHF 26298 11p13 1.28E-02 2.08E-02 2.03E-02 3.48E-02 8.97E-04 6.20E-03 yes
SRSF5 SFRS5, SRP4 6430 14q24 1.10E-02 1.85E-02 3.03E-02 4.61E-02 9.46E-04 6.42E-03 yes
JUNB AP-1 3726 19p13.2 1.99E-02 2.82E-02 2.13E-02 3.51E-02 1.16E-03 7.45E-03 yes
CDKN2C 1031 1p32 1.75E-02 2.57E-02 2.39E-02 3.82E-02 1.31E-03 8.12E-03 yes
DNAJA1 NEDD7 3301 9p13.3 2.04E-02 2.87E-02 2.14E-02 3.51E-02 1.33E-03 8.16E-03 yes
SH2B1 25970 16p11.2 3.18E-02 3.80E-02 4.04E-03 1.28E-02 1.62E-03 9.44E-03 yes
RAD51 5888 15q15.1 3.86E-02 4.34E-02 1.22E-02 2.43E-02 2.22E-03 1.17E-02 yes
Post-validation             
meta-analysisValidation cohortDiscovery cohort
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location P FDR P FDR P FDR Novel Ref
PYGB 5834 20p11.21 5.25E-07 1.71E-05 5.01E-02 6.28E-02 9.90E-08 5.84E-06 yes
CSNK2A1 CK2A1, CK2 1457 20p13 8.76E-08 3.55E-06 3.21E-01 2.59E-01 4.01E-06 1.10E-04 yes
DLX3 1747 17q21 3.29E-05 3.90E-04 6.37E-02 7.52E-02 5.79E-06 1.41E-04 yes
DUSP12 11266 1q21-q22 5.04E-05 5.19E-04 3.80E-02 5.31E-02 6.07E-06 1.43E-04 yes
ZMYND11 10771 10p14 8.32E-06 1.56E-04 2.39E-01 2.12E-01 7.26E-06 1.66E-04 yes
PIK3C3 5289 18q12.3 2.03E-04 1.29E-03 3.79E-02 5.31E-02 1.96E-05 3.34E-04 yes
WAS 7454 Xp11.4-p11.21 8.21E-05 6.95E-04 6.13E-02 7.34E-02 3.14E-05 4.86E-04 yes
HOXC10 3226 12q13.3 2.11E-04 1.33E-03 8.26E-02 9.16E-02 4.29E-05 6.10E-04 yes
MAGEB2 MAGE-XP-2 4113 Xp21.3 3.02E-04 1.64E-03 8.57E-02 9.39E-02 6.07E-05 8.16E-04 no [15]
MAFG 4097 17q25.3 1.12E-04 8.41E-04 2.37E-01 2.12E-01 7.13E-05 9.35E-04 yes
MARK4 57787 19q13.3 6.72E-04 2.73E-03 6.15E-02 7.34E-02 9.84E-05 1.17E-03 yes
NFKBIA IκBα 4792 14q13 1.02E-03 3.62E-03 3.76E-02 5.31E-02 9.87E-05 1.17E-03 yes
SERPINB5 5268 18q21.33 5.23E-04 2.33E-03 8.28E-02 9.16E-02 1.05E-04 1.23E-03 yes
PDCD6 10016 5p15.33 1.52E-04 1.07E-03 2.11E-01 1.95E-01 1.28E-04 1.44E-03 yes
TFE3 7030 Xp11.22 1.50E-03 4.71E-03 3.80E-02 5.31E-02 1.55E-04 1.69E-03 yes
RXRG 6258 1q22-q23 7.35E-04 2.89E-03 9.44E-02 9.96E-02 1.67E-04 1.75E-03 yes
RPS6KA6 27330 Xq21 7.62E-05 6.82E-04 6.00E-01 4.01E-01 1.81E-04 1.85E-03 yes
VAX2 25806 2p13 1.79E-03 5.21E-03 5.42E-02 6.73E-02 2.31E-04 2.26E-03 yes
MAGEB1 MAGE-Xp 4112 Xp21.3 1.09E-04 8.38E-04 4.43E-01 3.24E-01 2.41E-04 2.31E-03 no [15]
CLK1 1195 2q33 1.99E-03 5.54E-03 4.98E-02 6.28E-02 2.52E-04 2.37E-03 yes
PIAS2 9063 18q21.1 4.84E-04 2.22E-03 2.48E-01 2.14E-01 2.87E-04 2.59E-03 yes
NHLH1 4807 1q22 1.02E-03 3.62E-03 9.05E-02 9.83E-02 2.94E-04 2.61E-03 yes
PPM1A PP2Calpha 5494 14q23.1 2.92E-03 7.26E-03 4.14E-02 5.47E-02 2.94E-04 2.61E-03 yes
CASP9 842 1p36.21 5.54E-04 2.36E-03 1.92E-01 1.81E-01 2.97E-04 2.61E-03 yes
ZNF207 7756 17q11.2 1.52E-03 4.74E-03 7.49E-02 8.59E-02 2.99E-04 2.62E-03 yes
TBX6 6911 16p11.2 1.70E-03 5.05E-03 8.13E-02 9.16E-02 3.16E-04 2.72E-03 yes
GTF2E2 2961 8p12 4.00E-03 8.92E-03 3.97E-02 5.37E-02 3.64E-04 3.05E-03 yes
ZNF394 84124 7q22.1 3.37E-03 7.81E-03 4.94E-02 6.28E-02 4.13E-04 3.39E-03 yes
MRTO4 51154 1p36.13 7.12E-05 6.64E-04 4.00E-01 3.03E-01 4.27E-04 3.45E-03 yes
BRD2 RNF3 6046 6p21.3 6.86E-03 1.30E-02 3.49E-02 5.17E-02 6.09E-04 4.59E-03 yes
ZNF35 7584 3p21.32 6.06E-03 1.20E-02 4.01E-02 5.37E-02 6.84E-04 5.02E-03 yes
DEK 7913 6p22.3 3.74E-03 8.50E-03 8.18E-02 9.16E-02 7.71E-04 5.48E-03 no [14]
KRT14 3861 17q21.2 7.77E-04 3.02E-03 4.19E-01 3.09E-01 9.06E-04 6.21E-03 yes
GTF2B 2959 1p22-p21 8.63E-03 1.54E-02 5.57E-02 6.77E-02 1.09E-03 7.18E-03 yes
MKNK2 2872 19p13.3 1.35E-03 4.45E-03 3.68E-01 2.85E-01 1.20E-03 7.67E-03 yes
SECISBP2 79048 9q22.2 1.95E-03 5.52E-03 3.08E-01 2.51E-01 1.26E-03 7.98E-03 yes
CSNK2A2 CK2A2 1459 16q21 2.08E-03 5.65E-03 2.96E-01 2.45E-01 1.28E-03 7.99E-03 yes
DUSP14 11072 17q12 3.57E-03 8.21E-03 1.53E-01 1.51E-01 1.30E-03 8.08E-03 yes
TEK TIE-2 7010 9p21 2.03E-03 5.54E-03 2.95E-01 2.45E-01 1.39E-03 8.31E-03 yes
DAPK2 DRP-1 23604 15q22.31 1.34E-05 2.07E-04 7.31E-01 4.51E-01 1.65E-03 9.54E-03 yes
PHTF1 10745 1p13.2 9.48E-03 1.64E-02 7.15E-02 8.28E-02 1.65E-03 9.54E-03 yes
Post-validation           
meta-analysisDiscovery cohort Validation cohort
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Coefficients for multinomial elastic net regression model 
 
  
Ctrl SLE.1a SLE.1b SLE.2 SLE.3
(Intercept) 2.118 -1.885 -0.223 -1.019 1.010
TROVE2 -0.445 0.980 . . .
SSB/La -0.248 0.437 . . -0.094
SMN1 . . 0.232 . .
PSME3 -0.342 . 0.018 . .
RQCD1 . . 0.064 . -0.251
IGF2BP3 -0.092 . . . .
PABPC1 -0.126 . . . .
HNRNPA2B1 -0.478 . 0.340 . -0.184
APOBEC3G . . . 0.202 .
MAGEB2 . . 0.134 . -0.292
MAGEB1 . . . 0.154 .
HMGB2 -0.459 . . . .
SUB1 . . 0.494 . .
NHLH1 . . . . 0.057
CDC25B -0.314 . . . .
CARHSP1 -0.063 . . . .
HNRNPUL1 . . . 0.261 .
LYN . . . 0.061 .
MKNK2 . . . 0.654 .
DSTYK . . . 0.027 .
BRD2 . . . 0.277 .
RPL10 . . . 0.332 .
ME2 . . . 0.154 .
PRKRA . . . 0.554 .
VAV1 . . . . 0.344




Mixture discriminant analysis model canonical variate coefficients
Canonical var 1 Canonical var 2 Canonical var 3
APOBEC3G -0.187 -0.502 -0.225
BRD2 0.651 -0.123 0.228
CARHSP1 -0.045 0.723 0.398
CDC25B -0.132 0.620 -1.294
CLK1 0.224 0.819 0.103
DSTYK -0.422 -0.669 0.393
HMGB2 0.108 0.281 -0.203
HNRNPA2B1 -0.465 -0.230 0.172
HNRNPUL1 0.263 0.098 -1.094
IGF2BP3 -0.122 0.815 -0.593
LYN -0.181 1.871 0.196
MAGEB1 -0.014 -0.116 0.128
MAGEB2 0.246 0.268 -0.153
ME2 -0.005 0.105 0.245
MKNK2 0.117 -0.050 0.206
NHLH1 -0.118 0.111 -0.408
PABPC1 -0.501 -0.008 0.970
PRKRA 0.223 -0.037 0.085
PSME3 -0.156 1.217 0.488
RPL10 -0.831 0.296 -0.029
RQCD1 -0.309 0.038 0.092
SMN1 -0.349 -0.022 -0.227
SSB.La -0.797 -0.559 0.096
SUB1 -0.043 -0.444 -0.084
TROVE2 -0.537 -0.019 -0.266
VAV1 -0.683 -0.049 0.683
Centroid means for MDA clusters
Canonical var 1 Canonical var 2 Canonical var 3
Control.s1 1.120 -0.421 0.147
SLE.s1 0.412 -0.064 0.071
SLE.s2 -0.698 1.924 -4.433
SLE.s3 -1.793 4.876 1.490
SLE.s4 -5.880 -1.480 0.129
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